The generic name of Vomitinib is Vomitinib Mesylate Tablets, which is mainly used for the treatment of some non-small cell lung cancers, and it is recommended to take 2 tablets once a day.
Vomitinib Mesylate Tablet belongs to the third generation of epidermal growth factor receptor tyrosine kinase inhibitors, and is mainly used in the clinic for the treatment of non-small cell lung cancer used for the treatment of growth factor receptor-sensitive mutations and growth factor receptor T790M-resistant mutations. This product is commonly available in the form of 40mg/tablet, and is administered by oral administration of 2 tablets once a day.
Adverse reactions to this product include elevated transaminases, upper respiratory tract infections, cough, and diarrhea, and it is contraindicated in persons with known hypersensitivity to this product.
Please take the medication as prescribed after diagnosis by a physician and do not self-medicate.